Sugi Predict

Sugi Predict / Compounds / SCHEMBL2176927

SCHEMBL2176927

SCHEMBL2176927

CC(=O)N1CCC(O[C@@H]2CC[C@H](C(=O)N3CCN(c4ccccc4)CC3)[C@@](C)(C(=O)O)C2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.43
▸ TSHR P16473 2/20 0.43
▸ RAB9A P51151 2/20 0.43
▸ MAPT P10636 2/20 0.43
▸ POLB P06746 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ USP2 O75604 1/20 0.43
▸ NAMPT P43490 1/20 0.43
▸ KMT2A Q03164 1/20 0.42
▸ HRH3 Q9Y5N1 1/20 0.41
▸ ALDH1A1 P00352 2/20 0.40
▸ MAPK1 P28482 2/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ TFPI2 P48307 1/20 0.39
▸ TP53 P04637 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ ADAM10 O14672 3/20 0.39
▸ ERBB2 P04626 3/20 0.39
▸ MMP2 P08253 3/20 0.39
▸ MMP9 P14780 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2172058 0.83 KMT2A (0.45) LMNATSHRRAB9AMAPTPOLB
SCHEMBL2172833 0.80 KMT2A (0.49) LMNATSHRRAB9AMAPTPOLB
SCHEMBL2173712 0.80 KMT2A (0.49) LMNATSHRRAB9AMAPTPOLB
SCHEMBL3457449 0.77 SIGMAR1 (0.49) USP2NAMPTKMT2ATFPI2ADAM10
SCHEMBL2176970 0.76 CHRM2 (0.42) LMNATSHRRAB9AMAPTPOLB
SCHEMBL2176925 0.76 ADAM10 (0.49) NAMPTADAM10ERBB2MMP2MMP9
SCHEMBL2172688 0.74 ADAM10 (0.61) ADAM10ERBB2MMP2MMP9
SCHEMBL2173732 0.73 GPR119 (0.36) TSHRKMT2AHRH3ALDH1A1
SCHEMBL30555283 0.73 USP2 (0.50) RAB9APOLBUSP2NAMPTALDH1A1
SCHEMBL2173174 0.72 KMT2A (0.48) LMNATSHRRAB9AMAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9440958-B2 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION (US) 2016-09-13 — — US disclosed
US-20110224189-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES INCYTE CORPORATION 2011-09-15 — — US disclosed
US-7973041-B2 Antiarthritic agents; psoriasis; anticancer agents;antiallergens; metalloprotease inhibitors. INCYTE CORPORATION (US) 2011-07-05 — — US disclosed
US-7491724-B2 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION (US) 2009-02-17 — — US disclosed
US-20050113344-A1 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases INCYTE CORPORATION 2005-05-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224189-A1 SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES MMP25, MMP14, MMP9 LMNA 2321/4885TSHR 3573/4885RAB9A 2928/4885
US-20050113344-A1 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases MMP25, MMP2, MMP14 LMNA 2198/4885TSHR 3634/4885RAB9A 2818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.